Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 16/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.58 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.58 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.52 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | ATR | Q13535 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL373615 | 1.00 | PIK3CB (0.58) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL373616 | 1.00 | PIK3CB (0.58) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL373296 | 0.92 | PIK3CB (0.46) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL373297 | 0.92 | PIK3CB (0.46) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL373295 | 0.92 | PIK3CB (0.46) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL373441 | 0.89 | ATR (0.58) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL373440 | 0.89 | ATR (0.58) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL373392 | 0.89 | ATR (0.58) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL373393 | 0.89 | ATR (0.58) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL373391 | 0.89 | ATR (0.58) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071189-B2 | Heterocyclic compound and antitumor agent containing the same as active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2006-07-04 | — | — | US | claimed |
| EP-2409975-B1 | Solid dispersions comprising an amorphous body composed of a heterocyclic anti-tumor compound | ZENYAKU KOGYO KK (JP) | 2015-05-27 | — | — | EP | disclosed |
| US-8227463-B2 | Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2012-07-24 | — | — | US | disclosed |
| EP-2409975-A1 | Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2012-01-25 | — | — | EP | disclosed |
| US-20100249063-A1 | AMORPHOUS BODY COMPOSED OF HETEROCYCLIC COMPOUND, SOLID DISPERSION AND PHARMACEUTICAL PREPARATION EACH COMPRISING THE SAME, AND PROCESS FOR PRODUCTION OF THE SAME | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2218718-A1 | AMORPHOUS FORM OF HETEROCYCLIC COMPOUND, SOLID DISPERSION AND MEDICINAL PREPARATION EACH COMPRISING THE SAME, AND PROCESS FOR PRODUCTION OF THE SAME | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2010-08-18 | — | — | EP | disclosed |
| US-7307077-B2 | Heterocyclic compound and antitumor agent containing the same as effective ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2007-12-11 | — | — | US | disclosed |
| EP-1389617-B1 | HETEROCYCLIC COMPOUND AND ANTITUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KK (JP) | 2007-01-03 | — | — | EP | disclosed |
| US-20060247232-A1 | Heterocyclic compound and antitumor agent containing the same as effective ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2006-11-02 | — | — | US | disclosed |
| US-7071189-B2 | Heterocyclic compound and antitumor agent containing the same as active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2006-07-04 | — | — | US | disclosed |
| US-20040116421-A1 | Heterocyclic compound and antitumor agent containing the same as active ingredient | OHARA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1389617-A1 | HETEROCYCLIC COMPOUND AND ANTITUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249063-A1 | AMORPHOUS BODY COMPOSED OF HETEROCYCLIC COMPOUND, SOLID DISPERSION AND PHARMACEUTICAL PREPARATION EACH COMPRISING THE SAME, AND PROCESS FOR PRODUCTION OF THE SAME | SBDS, ABCG2, SSRP1 | PIK3CB 4109/4885PIK3CA 3548/4885PIK3CD 4060/4885 |
| US-20060247232-A1 | Heterocyclic compound and antitumor agent containing the same as effective ingredient | CBR3, HCCS, CBR1 | PIK3CB 3376/4885PIK3CA 2412/4885PIK3CD 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.